Home > News

Analysis of the Development Environment for Pharmaceutical Intermediates in China: Crisis and Opportunity Coexist

Release time: 2024-04-01 21:10:01

The pharmaceutical industry is an important component of China's national economy and closely related to people's health. It is an important industry related to the construction of a harmonious society. In recent years, China has introduced a series of policies to support and guide the rapid development of the pharmaceutical manufacturing industry, encouraging its development and innovation. The formulation of relevant industrial policies provides clear and broad market prospects for the development of pharmaceutical manufacturing and pharmaceutical intermediate industries, and provides a good production and business environment for enterprises.

In order to meet the continuous development of the pharmaceutical industry, China's pharmaceutical intermediate industry will shift from the traditional mode of low-level repetition, lack of innovation, and extensive production to the direction of innovation, upgrading, high-quality, and high-level development. With the advancement of research and development work and the accumulation of independent intellectual property rights, the product added value and process complexity of pharmaceutical intermediates will continue to increase, becoming a strong guarantee for the development of the pharmaceutical industry. The number of patent applications for pharmaceutical intermediates in China has maintained an upward trend until 2020, with a decrease of 442 applications in 2021. Since 2022, there have been 214 patent applications for pharmaceutical intermediates in China.

Keywords: Peptide,Custom peptide,Cosmetic peptide,Semaglutide,Tirzepatide,Retatrutide etc